Literature DB >> 18989988

Has molecular and cellular imaging enhanced drug discovery and drug development?

Gang Niu1, Xiaoyuan Chen.   

Abstract

A great many efforts have been made to accelerate the drug discovery and development process, which is extremely time and money consuming. Recently developed molecular imaging has many significant advantages over conventional methods for examining molecular pathways and obtaining pharmacokinetic, pharmacodynamic and mechanistic information. This review briefly summarizes various molecular and cellular imaging techniques and discusses several important applications of molecular and cellular imaging in drug discovery and development, which include: (i) measurement of pharmacodynamic endpoints by imaging metabolism and proliferation, imaging angiogenic parameters, and imaging a particular pathway or downstream target; (ii) evaluation of pharmacokinetics; and (iii) imaging therapeutic gene expression with relevance to gene therapy. Molecular imaging is becoming more widely used as a non-invasive tool for drug discovery and drug screening. Further refinements in imaging techniques, optimization of imaging probes and collaborative efforts will be needed to fully realise the vast potential of molecular imaging techniques in discovering and developing new drugs.

Mesh:

Year:  2008        PMID: 18989988     DOI: 10.2165/0126839-200809060-00002

Source DB:  PubMed          Journal:  Drugs R D        ISSN: 1174-5886


  17 in total

1.  Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells.

Authors:  Jeremy I Pearl; Andrew S Lee; Dennis B Leveson-Gower; Ning Sun; Zhumur Ghosh; Feng Lan; Julia Ransohoff; Robert S Negrin; Mark M Davis; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2011-03-04       Impact factor: 24.633

2.  Evaluation of 99mTc-labeled cyclic RGD dimers: impact of cyclic RGD peptides and 99mTc chelates on biological properties.

Authors:  Yang Zhou; Young-Seung Kim; Xin Lu; Shuang Liu
Journal:  Bioconjug Chem       Date:  2012-03-06       Impact factor: 4.774

3.  Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.

Authors:  Sudipta Chakraborty; Jiyun Shi; Young-Seung Kim; Yang Zhou; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

4.  PET imaging of EGF receptors using [18F]FBEM-EGF in a head and neck squamous cell carcinoma model.

Authors:  Weihua Li; Gang Niu; Lixin Lang; Ning Guo; Ying Ma; Dale O Kiesewetter; Joseph M Backer; Baozhong Shen; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-23       Impact factor: 9.236

Review 5.  Molecular imaging of cell-based cancer immunotherapy.

Authors:  Gang Liu; Magdalena Swierczewska; Gang Niu; Xiaoming Zhang; Xiaoyuan Chen
Journal:  Mol Biosyst       Date:  2011-02-09

6.  2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.

Authors:  Jiyun Shi; Young-Seung Kim; Sudipta Chakraborty; Bing Jia; Fan Wang; Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-07-15       Impact factor: 4.774

7.  Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.

Authors:  Gang Niu; Zibo Li; Qizhen Cao; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-14       Impact factor: 9.236

Review 8.  Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2009-12       Impact factor: 4.774

9.  99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics.

Authors:  Jiyun Shi; Lijun Wang; Young-Seung Kim; Shizhen Zhai; Bing Jia; Fan Wang; Shuang Liu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-30       Impact factor: 9.236

10.  Opening up the optical imaging window using nano-luciferin.

Authors:  Apurva R Patel; Ed Lim; Kevin P Francis; Mandip Singh
Journal:  Pharm Res       Date:  2014-05-16       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.